Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi‐Long Wu, Tae Min Kim, Valentina Guarneri et al.|The Lancet Oncology|2024Cited by 98
Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatmentPasi A. Jänne, Melissa L. Johnson, Frédéric Bigot et al.|Molecular Cancer Therapeutics|2023Cited by 60
A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.Gerald S. Falchook, Anthony J. Olszanski, Cong Li et al.|Journal of Clinical Oncology|2021Cited by 10